Drug Profile


Alternative Names: AM 0010; PEG-rHuIL-10; PEGylated Interleukin-10; PEGylated recombinant human Interleukin-10

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer ARMO Biosciences
  • Class Anti-inflammatories; Interleukins; Polyethylene glycols
  • Mechanism of Action Cholesterol modulators; Cytotoxic T lymphocyte stimulants; Immunomodulators; Interleukin 23 inhibitors; Interleukin-10 replacements; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Preclinical Fibrosis; Hypercholesterolaemia; Inflammatory bowel diseases

Most Recent Events

  • 22 Dec 2016 PEG-ilodecakin receives Orphan Drug status for Pancreatic cancer in European Union
  • 14 Nov 2016 PEG-ilodecakin receives Orphan Drug status for Pancreatic cancer in USA
  • 14 Nov 2016 PEG-ilodecakin receives Fast track status from the US FDA for Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top